AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women

Bone

Volumn 64, Issue , 2014, Pages 204-210

  John, Markus R ^a   Harfst, Evita ^a   Loeffler, Juergen ^a   Belleli, Rossella ^a   Mason, June ^a   Bruin, Gerard J M ^b   Seuwen, Klaus ^b   Klickstein, Lloyd B ^b   Mindeholm, Linda ^a   Widler, Leo ^b   Kneissel, Michaela ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Bone formation; Calcilytics; Osteoporosis; Parathyroid hormone; Teriparatide

Indexed keywords

AXT 914; AXT914; CALCIUM; CALCIUM SENSING RECEPTOR; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHOSPHATE; PLACEBO; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; QUINAZOLINONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALCIUM BLOOD LEVEL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DESIGN; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EYE DISEASE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; OSSIFICATION; OSTEOPOROSIS; POSTMENOPAUSE; REPRODUCIBILITY; SINGLE DRUG DOSE; SKIN DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; VASCULAR DISEASE; CASE CONTROL STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; PARATHYROID HORMONE; PLACEBOS; POSTMENOPAUSE; QUINAZOLINONES;

EID: 84899713793     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.04.015     Document Type: Article

References (24)

1. Silverman S.L. Quality-of-life issues in osteoporosis. Curr Rheumatol Rep 2005, 7(1):39-45.
2. Das S., Crockett J.C. Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther 2013, 7:435-448.
3. Baron R., Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab 2012, 97(2):311-325.
4. Reeve J., Hesp R., Williams D., Hulme P., Klenerman L., Zanelli J.M., et al. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1976, 1(7968):1035-1038.
5. Chakravarti B., Chattopadhyay N., Brown E.M. Signaling through the extracellular calcium-sensing receptor (CaSR). Adv Exp Med Biol 2012, 740:103-142.
6. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344(19):1434-1441.
7. Glover S.J., Eastell R., McCloskey E.V., Rogers A., Garnero P., Lowery J., et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009, 45(6):1053-1058.
8. Schwietert H.R., Groen E.W., Sollie F.A., Jonkman J.H. Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. Clin Pharmacol Ther 1997, 61(3):360-376.
9. Widler L. Calcilytics: antagonists of the calcium-sensing receptor for the treatment of osteoporosis. Future Med Chem 2011, 3(5):535-547.
10. John M.R., Widler L., Gamse R., Buhl T., Seuwen K., Breitenstein W., et al. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone 2011, 49(2):233-241.
11. Widler L., Gamse R., Seuwen K., Buhl T., Beerl R., Breitenstein W., et al. A novel calcium-sensing receptor antagonist leads to dose-dependent transient release of parathyroid hormone after oral administration to healthy volunteers - an initial proof-of-concept for a potential new class of anabolic osteoporosis therapeutics. J Bone Miner Res 2008, (Suppl. 1):S1173.
12. John M.R., Harfst E., Loeffler J., Belleli R., Zack J., Ruckle J. A 4-week study of AXT914, a novel calcilytic compound for oral bone anabolic osteoporosis therapy in postmenopausal women. J Bone Miner Res 2010, (Suppl. 1):SU0372.
13. Kumar S., Matheny C.J., Hoffman S.J., Marquis R.W., Schultz M., Liang X., et al. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone 2010, 46(2):534-542.
14. Fitzpatrick L.A., Dabrowski C.E., Cicconetti G., Gordon D.N., Papapoulos S., Bone H.G., et al. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2011, 96(8):2441-2449.
15. Bilezikian J.P. Anabolic therapy for osteoporosis. Womens Health (Lond Engl) 2007, 3(2):243-253.
16. Fitzpatrick L.A., Dabrowski C.E., Cicconetti G., Gordon D.N., Fuerst T., Engelke K., et al. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res 2012, 27(2):255-262.
17. Fitzpatrick L.A., Smith P.L., McBride T.A., Fries M.A., Hossain M., Dabrowski C.E., et al. Ronacaleret, a calcium-sensing receptor antagonist, has no significant effect on radial fracture healing time: results of a randomized, double-blinded, placebo-controlled phase II clinical trial. Bone 2011, 49(4):845-852.
18. John M.R., Goodman W.G., Gao P., Cantor T.L., Salusky I.B., Jüppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999, 84(11):4287-4290.
19. Caltabiano S., Dollery C.T., Hossain M., Kurtinecz M.T., Desjardins J.P., Favus M.J., et al. Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women. Bone 2013, 56(1):154-162.
20. Loupy A., Ramakrishnan S.K., Wootla B., Chambrey R., de la Faille R., Bourgeois S., et al. PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor. J Clin Invest 2012, 122(9):3355-3367.
21. El-Sherif N., Turitto G. Electrolyte disorders and arrhythmogenesis. Cardiol J 2011, 18(3):233-245.
22. Park S.Y., Mun H.C., Eom Y.S., Baek H.L., Jung T.S., Kim C.H., et al. Identification and characterization of D410E, a novel mutation in the loop 3 domain of CASR, in autosomal dominant hypocalcemia and a therapeutic approach using a novel calcilytic, AXT914. Clin Endocrinol (Oxf) 2013, 78(5):687-693.
23. Ward B.K., Magno A.L., Walsh J.P., Ratajczak T. The role of the calcium-sensing receptor in human disease. Clin Biochem 2012, 45(12):943-953.
24. Riccardi D. Antagonizing the calcium-sensing receptor: towards new bone anabolics?. Curr Mol Pharmacol 2012, 5(2):182-188.